Myriad Genetics, Inc. (NASDAQ:MYGN) VP Gary A. King sold 3,120 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $38.12, for a total value of $118,934.40. Following the transaction, the vice president now directly owns 125,088 shares in the company, valued at approximately $4,768,354.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Myriad Genetics, Inc. (NASDAQ MYGN) opened at $38.62 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The firm has a market capitalization of $2,674.09, a price-to-earnings ratio of 35.43, a PEG ratio of 2.45 and a beta of 0.24. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $38.65.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS. sell-side analysts forecast that Myriad Genetics, Inc. will post 1.05 earnings per share for the current year.

MYGN has been the topic of several research reports. BTIG Research initiated coverage on Myriad Genetics in a report on Friday, January 5th. They set a “buy” rating and a $41.00 price objective on the stock. Morgan Stanley reaffirmed an “underweight” rating and set a $24.00 price objective (up previously from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Barclays reaffirmed a “hold” rating and set a $30.00 price objective on shares of Myriad Genetics in a report on Monday, January 8th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective on the stock in a report on Tuesday, October 17th. Finally, ValuEngine raised Myriad Genetics from a “hold” rating to a “buy” rating in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $30.09.

Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its stake in shares of Myriad Genetics by 18.4% in the 4th quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock valued at $75,743,000 after purchasing an additional 343,196 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Myriad Genetics by 4.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 660,729 shares of the company’s stock valued at $22,693,000 after purchasing an additional 29,797 shares during the period. Convergence Investment Partners LLC acquired a new position in shares of Myriad Genetics in the 4th quarter valued at $3,787,000. Louisiana State Employees Retirement System lifted its stake in shares of Myriad Genetics by 7.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 29,800 shares of the company’s stock valued at $1,023,000 after purchasing an additional 2,100 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its stake in shares of Myriad Genetics by 5.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 353,673 shares of the company’s stock valued at $12,796,000 after purchasing an additional 17,439 shares during the period.

TRADEMARK VIOLATION WARNING: “Gary A. King Sells 3,120 Shares of Myriad Genetics, Inc. (MYGN) Stock” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/gary-a-king-sells-3120-shares-of-myriad-genetics-inc-mygn-stock/1816942.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.